What They List
- Psilocybin Clinical Trial
- Study Screening Information
- Research Participation Details
Research
NCT06001749 - Psilocybin in Cancer Pain Study
Clinical Trial in Boston, Massachusetts
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative) Source record lists lead sponsor Yvan Beaussant, MD, MSci and overall status Recruiting.
Clinical TrialResearch
Directory Facts
- Status
- Verified from official/source records
- Price
- Free study screening / research participation
- Hours
- Verify with provider
- License / Record
- NCT06001749
- Last Verified
- 2026-06-12
Location
Dana-Farber Cancer Institute, Boston, Massachusetts
Source Notes
Discovery row generated from the official ClinicalTrials.gov API record for NCT06001749; status Recruiting; sponsor Yvan Beaussant, MD, MSci.
Source: https://clinicaltrials.gov/study/NCT06001749
MagicMushroomsDirectory does not provide medical, legal, or purchasing advice. Verify current laws, provider status, and eligibility before contacting any listing.